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Abstract 
 
Background: In order to identify biomarkers useful for the diagnosis of genetic 
white matter disorders we compared the metabolic profile of patients with 
leukodystrophies with a hypomyelinating or a non-hypomyelinating MRI 
pattern. Methods: We used a non-a priori method of in vitro 1H-NMR 
spectroscopy on CSF samples of 74 patients with leukodystrophies. Results: 
We found an elevation of CSF N-acetylaspartylglutamate (NAAG) in patients 
with Pelizaeus-Merzbacher disease (PMD) – PLP1 gene –, Pelizaeus-
Merzbacher-like disease – GJC2 gene – and Canavan disease – ASPA gene. 
In the PMD group, NAAG was significantly elevated in the CSF of all patients 
with PLP1 duplication (19/19) but was strictly normal in 6 out of 7 patients with 
PLP1 point mutations. Additionally, we previously reported increased CSF 
NAAG in patients with SLC17A5 mutations. Conclusions: Elevated CSF 
NAAG is a biomarker that suggests specific molecular diagnostic 
abnormalities in patients with white matter diseases. Our findings also point to 
unique pathological functions of the overexpressed PLP in PMD patients with 
duplication of this gene. 
 
Key words: NMR spectroscopy – N-acetylaspartylglutamate – biomarker – 
leukodystrophy – Pelizaeus-Merzbacher disease. 
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Introduction 
 
Elevation of CSF N-acetylaspartylglutamate (NAAG) in some 
leukodystrophies has been previously described but its relationship to disease 
is poorly understood, with the exception of Canavan disease where the 
elevation of N-acetylaspartate (NAA) may be directly implicated [1]. 
Using two capillary electrophoresis systems, NAAG has been shown to be 
elevated in the CSF of 29 out of 32 patients with a clinical presentation of 
Pelizaeus Merzbacher disease (PMD) [2]. This included 22 patients with PLP1 
mutations and 7 patients with Pelizaeus-Merzbacher-like disease (PMLD). 
However, the nature of the mutations was not reported either in the PMD or 
the PMLD groups. An increase of NAAG was also observed in the CSF of one 
patient with Canavan disease [3], one PMLD patient harboring a homozygous 
deletion in the GJC2 gene [4] and two patients with a severe hypomyelination 
pattern of unknown cause [5]. In addition, we recently reported that CSF 
NAAG was increased in 6 patients with sialic acid storage disease (SASD) 
associated with SLC17A5 mutations[6].  
 
Therefore, we decided to use proton NMR spectroscopy (1H-NMRS) to 
determine whether the levels of CSF NAAG can facilitate the molecular 
diagnosis of patients with leukodystrophies with a hypomyelinating or a non-
hypomyelinating pattern on brain MRI [7]. 
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Material and Methods 
 
Patients 
Seventy-four children and adults from two referral centers for neurogenetics 
and neurometabolism were enrolled in clinical protocols approved by the 
ethics committees of the Hôpital de Clermont-Ferrand, France, and the 
National Institutes of Neurological Disorders and Stroke, Bethesda, MD, USA. 
Written informed consent was obtained from all patients or their legal 
guardians.  
 
The cohort of patients with leukodystrophies with a hypomyelinating pattern 
consisted of (i) 26 male patients with PLP1 mutations presenting as PMD or 
X-linked spastic paraplegia type 2 [8] – PMD/SPG2 patients – , including 19 
patients with PLP1 duplication and 7 patients with PLP1 missense or splice 
mutations (Table 1); (ii) 9 patients with PMLD including one patient with GJC2 
mutations; and (iii) 10 patients with a leukodystrophy of unknown etiology 
despite extensive metabolic and genetic testing. The rest of the cohort 
consisted of 14 patients with leukodystrophies with a non-hypomyelinating 
pattern – including patients with Canavan disease, merosin deficiency, MLC1 
mutation and complex I deficiency – and 15 diseased controls with complex 
neurological diseases but normal brain MRI.  
 
Methods 
In order to assess clinical severity, we used a score previously validated in 
patients with PLP1 mutations [9]. Briefly, form 0 referred to absence of motor 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
NAAG in CSF of patients with leukodystrophies 
 6 
achievement; form 1 – head control between 2 and 4 years; form 2 – sitting 
position between 2 and 5 years; form 3 – sitting position between 1 and 2 
years, walk with support at a mean age of 3.5 1.5 years (range 2-6); form 4 – 
autonomous walking. 
 
Frozen CSF – stored at -80°C – were prepared for 1H-NMRS with minimal 
handling [5, 10]. First, CSF samples were deproteinized using a 10kDa filter 
(Nanosep, Omega) to avoid interference from high molecular weight species 
such as lipoproteins. Before use, the filter was washed twice with water by 
centrifugation to remove glycerol. A 100µl aliquot of 3.89 mM [trimethylsilyl]-
2,2,3,3-tetradeuteropropionic acid in 2H2O (TSP-2H2O, Aldrich) was then 
added to 500 µl of the ultrafiltrate, providing a chemical shift reference 
( =0.00ppm), a concentration reference and a deuterium lock signal. The pH 
of the ultrafiltrate was adjusted to 2.50± 0.05 with concentrated HCl. Finally, 
500µl of the sample was placed in a 5 mm NMR tube (Wilmad Royal 
Imperial). The proton NMR spectra were determined on an Avance-500 SB 
spectrometer (Bruker, France) equipped with a 5 mm BBI (broadband inverse) 
probe; samples were not spun. Spectra were collected at 25°C and consisted 
in 32K data points with a spectral width of 6,000 Hz and a total acquisition 
times of 27 min. A 90° radiofrequency pulse, following a water signal 
presaturation of 10s, was used for each 128 scans. Shimming of the sample 
was performed on the deuterium signal until the resonance line width for TSP 
was <1Hz. Before a Fourier transformation into 64K data points, a sine 
window multiplication (sine bell shift of 90°) was used to reduce noise. The 
phase and the baseline were corrected manually using the spectrometer 
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software (X-Win NMR 3.5, Bruker, France). Two-dimensional proton NMRS, 
1H-1H correlation spectroscopy (COSY), was performed to confirm the 
identification of metabolites of interest in patients’ body fluids. The spectra 
were recorded at 500 MHz using 4k datapoints in F2 and a spectral width of 
6002 Hz. 256 Increments and 16 scans per increment were used. The TR 
was 1.5 s, during which the water resonance was presaturated. Prior to 
Fourier transformation, a sine window multiplication was applied in both time 
domains. The values of NAAG were calculated by comparison with the known 
concentration of the internal standard (TSP). 
 
A one-way between groups analysis of covariance was conducted to compare 
the levels of CSF NAAG between PMD/SPG2 patients with PLP1 duplication 
and PLP1 point mutations using age and clinical score as covariates. 
Preliminary checks were conducted to ensure that there was no violation of 
the assumptions of normality, linearity, homogeneity of variances and 
homogeneity of regression slopes. 
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Results 
 
Elevated CSF NAAG in patients with PLP1, GJC2 and ASPA mutations  
In a 1-dimensional 1H-NMR spectrum (pH=2.5), NAAG presents as a 
prominent singlet resonance at 2.04 ppm and smaller resonances at 2.01 and 
2.23 (multiplets), 2.47 (triplet), 2.81 and 2.91 (doublet of doublets), 4.32 
(doublet of doublets), and 4.72 ppm (doublet of doublets) [11]. Characteristic 
cross peaks in 2-dimensional COSY 1H-NMRS are shown in Figure 1. 
 
Compared to our group of disease controls, in vitro 1H-NMRS of CSF showed 
a significant elevation of NAAG in the CSF of PMD/SPG2 patients compared 
to controls (47 44 mol/L vs 5 1 mol/L, p<0.001). The mean values of 
NAAG were normal in (i) patients with PMLD, (ii) patients with other 
leukodystrophies with a hypomyelinating MRI pattern, and (iii) patients with 
leukodystrophies with a non-hypomyelinating pattern (Figure 2). However, 1H-
NMRS revealed a mild to moderate elevation in the CSF of one PMLD patient 
associated with GJC2 compound heterozygous mutations (14 mol/L), one 
patient with Canavan disease associated with ASPA mutations (17 mol/L), 
and two patients presenting with a hypomyelinating leukodystrophy of 
unknown etiology (33 and 60 mol/L respectively) (Figure 2). Of note, we did 
not observe any CSF elevation of NAA except in the CSF of the patient with 
Canavan disease (98 mol/L, Figure 3). 
 
Association of elevated CSF NAAG with the nature of the PLP1 mutation 
rather than clinical severity 
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1H-NMRS revealed an elevation of NAAG in the CSF of all 19 patients with 
PLP1 duplication (Table 1and Figure 2). Conversely, CSF NAAG was strictly 
normal in 6 out of 7 patients with PLP1 missense, nonsense or splice 
mutations (Table 1and Figure 2). The only patient with PLP1 mutations who 
displayed a significant elevation of CSF NAAG presented with the most 
severe clinical presentation – clinical score of 0 (Table 1). However, there was 
no correlation between the levels of CSF NAAG and clinical severity among 
the cohort of PMD/SPG2 patients, or among patients with PLP1 duplication 
only. There was no correlation either between CSF NAAG and age. Moreover, 
when adjusting for both age and clinical severity, we found a significant 
elevation of NAAG in patients with PLP1 duplication versus PLP1 point 
mutations (p=0.012, partial eta squared=0.265). Therefore, the elevation of 
NAAG in the CSF of PMD/SPG2 patients strongly suggests the nature of the 
mutation – i.e. duplication in the PLP1 gene – rather than clinical severity.  
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Discussion 
 
In this study, using in vitro 1H-NMRS we showed that NAAG is always 
elevated in the CSF of patients with PLP1 duplication. We also confirmed 
increased CSF NAAG in patients with GJC2 mutations and Canavan disease 
[2, 3]. Despite the elevation of CSF NAAG in one patient with a PLP1 point 
mutation displaying a very severe form of the disease, we did not find any 
correlation between the levels of CSF NAAG and clinical severity in 
PMD/SPG2 patients, which is consistent with our recent findings in SASD 
patients [6]. Since we had relatively few patients with mutated PLP1 and 
severe clinical score (0-1), we cannot completely exclude that some patients 
with severe missense mutation also have elevated CSF NAAG. Nevertheless, 
there was a marked difference in the levels of CSF NAAG between the 
patients with PLP1 duplication and those with PLP1 point mutations, even 
when adjusting for clinical severity. Therefore, we suggest that quantifying 
NAAG levels in CSF of patients with white matter diseases can be a useful 
and simple tool to orient molecular diagnostic testing, especially in 
hypomyelinating leukodystrophies. Of note, in vivo 1H-MRI spectroscopy is 
unable to provide similar information since the technique cannot discriminate 
between the NAA and NAAG peaks unlike in vitro 1H-NMRS (Figure 3). 
Consequently, the relatively high NAA concentrations in brain tissues prevent 
the measurement of NAAG in vivo. The detection limit of 1H-NMRS for CSF 
NAAG is higher than of techniques such as two capillary electrophoresis [2] or 
mass spectrometry (personal observation). However, contrary to these 
techniques, 1H-NMRS requires no derivatization or extraction. It can therefore 
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simultaneously detect compounds of different nature which allows the non-a 
priori identification of new metabolic abnormalities in patients with 
uncharacterized or known genetic diseases [6, 12]. 
 
The absence of correlation between CSF NAAG and clinical severity in 
PMD/SPG2 and SASD patients, as well as the observed neuroprotective 
effect of increased extracellular NAAG during GCPII inhibition [13], suggest 
that NAAG is an unlikely contributor to the hypomyelination phenotype 
observed in these patients. NAAG undergoes a tricellular metabolic sequence 
wherein it is synthesized in neurons from N-acetylaspartate (NAA) and L-
glutamate, hydrolyzed to NAA and glutamate by astrocytes and further 
hydrolyzed to L-aspartate and acetate by oligodendrocytes [14]. NAA was 
also shown to provide acetyl groups for myelin synthesis [15]. It is therefore 
possible that the elevation of CSF NAAG in some hypomyelinating disorders 
reflects a compensatory mechanism for the altered maturation of 
oligodendrocytes in an effort to enhance myelin synthesis.  
 
The elevation of CSF NAAG in patients with PLP1 duplication, but usually not 
in patients with point mutations, favors a specific effect of the over-expressed 
wild-type PLP1 gene as supported by in vitro and preclinical in vivo studies 
[16, 17]. Overexpression of wild-type PLP in the CNS may affect the integrity 
of neurons as suggested by the increased mortality of neurons when cultured 
in the presence of conditioned media from PLP overexpressing cells but not 
from DM20 – a splice variant of PLP – overexpressing cells. This effect of 
conditioned media may be mediated by a negative pH shift elicited by PLP 
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[18] and could be related to the similarity of PLP and its four hydrophobic 
domain motif to proteins that are known to function as pores or channels [19]. 
Interestingly, abnormal connexin 47 associated with GJC2 gene mutations 
was reported to alter the function of intercellular channels [20]. The sialin 
transporter, which was recently found to also function as an aspartate 
transporter [21], may have a role in neuronal secretory processes due to its 
additional non-lysosomal localization [22]. Therefore, the implication of PLP1, 
connexin 47 and sialin in the formation of ion channels/transporters in 
membranes suggests increased excretion of NAAG into the extracellular 
compartment. The lack of concurrent elevation of NAA further supports the 
hypothesis that NAAG elevation in CSF of patients with PLP1 duplication 
results from excessive neuronal release of NAAG rather than from its over-
production. We found two patients presenting with hypomyelination on brain 
MRI and increased CSF NAAG but without mutations of PLP1, GJC2 or 
SLC17A5. A similar entity has been previously reported [5]. In these cases, a 
candidate genes approach should focus on genes encoding for proteins 
related to the structure and function of ion channels or transporters. 
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Table 1: Genetic, biochemical and clinical characteristics of PMD/SPG2 
patients. 
 
PLP1 Mutation NAAG ( mol/L)* Age Clinical Score 
p.Cys109TrpfsX11 ND 3 3 
p.Asp103ThrfsX12 ND 17 3 
p.Val219Phe ND 38 3 
c.IVS4+1G>A / p.Val209GlufsX27 ND 9 3 
p.Leu223Phe 38 10 0 
p.Cys220Tyr ND 10 3 
p.Asp103ThrfsX12 ND 18 4 
Duplication 30 2 1 
Duplication 36 6 3 
Duplication 40 2 2 
Duplication 65 6 3 
Duplication 89 5 3 
Duplication 32 17 2 
Duplication 84 8 2 
Duplication 60 11 3 
Duplication 47 4 3 
Duplication 106 13 2 
Duplication 36 8 3 
Duplication 56 5 2 
Duplication 205 8 1 
Duplication 88 9 1 
Duplication 55 3 1 
Duplication 32 5 2 
Duplication 23 3 1 
Duplication 53 5 3 
Duplication 52 7 2 
 
* Diseased controls, mean= 5 1 mol/L (n=15). ND: below detection limit (<3 
mol/L). 
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Figure legends 
 
Figure 1: One-dimensional and 2-dimensional (COSY) 1H-NMR spectra of 
NAAG in CSF. The upper part shows the methyl signal (CH3 of NAAG) in the 
1D spectrum (2.04 ppm). The lower part shows the correlations between the 
two diastereotopic protons of CH2 (H17) – 2 doublets of doublets at 2.91 and 
2.85 ppm – and the correlations between the two diastereotopic protons of 
CH2 (H8) – multiplets at 1.99 and 2.23 ppm – and the two protons of CH2 (H9) 
– triplet at 2.43 ppm – in the 2D spectrum. The signals of protons of CH2 (H8) 
and CH2 (H9) are not visible on the 1D spectrum because of their small 
intensities and of overlapping with glutamate and methyl signals. 
 
Figure 2: Values of CSF NAAG in the cohort of 74 patients. The dotted line 
represents the upper limit of normal values of CSF NAAG (12 mol/L [5]). 
DUP: duplication; MUT: point mutation; PMLD: Pelizaeus-Merzbacher-like 
disease; UL: unknown leukodystrophy. Circles and stars denote outliers that 
are farther than 1.5 and 3 interquartile ranges respectively from the nearer 
edge of the box. 
 
Figure 3: 1H-NMR spectra of CSF from 2.0 to 2.2 ppm showing the signals of 
NAA (singlet at 2.033 ppm), N-acetylneuraminic acid (NANA; singlet at 2.047 
ppm), NAAG (singlet at 2.040 ppm) and and glutamic acid (multiplet at 2.16 
ppm). CSF of a patient with (a) Canavan disease showing a marked elevation 
of NAA (98 mol/L) and a moderate elevation of NAAG (17 mol/L): (b) PLP1 
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duplication showing elevated NAAG (55 mol/L), compared to (c) normal CSF 
spectrum. 
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